Macroaxis: Personalized Investing
Simple Personalized Investing

SP 500   1,651   4.84  Index Moved Down -0.29%
FNMFO FNMFO 096770 KDDIF Iron Large Value Hybrid Mix Advertising 
United States GSPC USD ...  |  Investing Themes


Processing
Collecting data for ARYX

ARYx quote and profile

 
 Companies |  Insiders  | Dashboard  
     
It looks like this equity (ARYX.PK) cannot be resolved or is no longer available, but we have found another equity that may match the characteristics of what you are looking for. Please check ARYX ARYx Therapeutics Inc to make sure you are using current equity.
0.0
  
OTC STOCK
0.00  No Change   0.00%  
May 23 2013 

ARYx Alert!

ARYx Therapeutics Inc cannot be verified agains its exchange. It seems like ARYx is not available for investing. Please verify the symbol is currently traded on OTC Market. If you still believe the symbol you are trying to look up is valid please let us know and we will check it as soon as possible.
Check current 30 days ARYx correlation with market (S&P 500)
1 Month Beta 0.0  
Highest Price:  
Lowest Price:  
0.01  
0.0  
May 14 2013 
April 23 2013 
Unless we do not have data at the moment the returns on S&P 500 and ARYx are completely uncorrelated
ARYx Therapeutics Inc not significant BetaARYx Therapeutics Beta Legend
ARYX United States OTC
ARYx Therapeutics Inc
Benchmark S&P 500
http://www.aryx.com
Contact Number: 510. 585. 2200
Traded on OTC Market
    
Current Valuation8.95 M
Shares Outstanding33.46 M
Number of Shares Shorted75.67 K
Cash and Equivalents2.95 M
 United States Nasdaq   0.97 % Macroaxis: 0.97 Moved Up  
 
 United States Russel   0.21 % Macroaxis: 0.21 Moved Up  
 
 thisGreen ARYX ARYX.PK agains markets  0.00 % No Change  
 United States SP 500   0.29 % Macroaxis: 0.29 Moved Down  
 
 United States NYSE   0.44 % Macroaxis: 0.44 Moved Down  
 
Compare to Competition Get Alpha   Get Advice

ARYx Leadership

Paul Goddard Chairman of the Board, CEO
David Nagler Vice President - Corporate Affairs, Secretary
John Varian COO

Try other equities

United States ARY  Ares Capital Corporation  Stock  NYSE 
United States ARYC  Arrayit Corporation  OTC Equity  OTC BB 
United States ARYC  Arrayit Corporation  OTC Stock  OTC 
United States ARYMF  Argosy Minerals Limited  OTC Stock  OTC 
United States ARYTF  Aryt Industries Ltd  OTC Stock  OTC 
United States ARYCE  ARRAYIT CORPORATION  OTC Equity  OTC BB 
United States ARYMF  ARGOSY MINERL UT CDA  Stock  OTC 

ARYx Price and Market Media

The median price of ARYx for the period between Tue, Apr 23, 2013 and Thu, May 23, 2013 is 0.0 with a coefficient of variation of 291.04. The daily time series for the period is distributed with a sample standard deviation of 0.0, arithmetic mean of 0.0, and mean deviation of 0.0. The Stock did not receive any noticable media coverage during the period.
ARYx         SP 500
Price Growth (%)
 

ARYx Summary

ARYx Therapeutics Inc [ARYX] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Nano-Cap' category with current market capitalization of 334.61 K. ARYx Therapeutics Inc has 33.46 M outstanding shares of which 75.67 K shares are presently shorted by private and institutional investors with about 0.8 days to cover all short positions.

Currently Trending  

 WMCO 
 ASE United States 
 6 minutes ago
Traded for 15.4 
 LLNW 
 NMS United States 
 6 minutes ago
Traded for 2.06 
 FPTB 
 ASE United States 
 6 minutes ago
Traded for 13.2 
 MSDXP 
 ASE United States 
 6 minutes ago
Traded for 26.67 
 CZWI 
 NGM United States 
 6 minutes ago
Traded for 7.13 
ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with commercialized drugs in the United States. more
Past Market
Over 30
Days
0
Out Of
100
 
Chance of
More
Than
97 %
 
Follow ARYx with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add ARYx to your reader
 

ARYx Research Report

ARYx vs. Federal

Correlation analysis and fundamentals comparison between ARYx Therapeutics and Federal National Mor

ARYx Executives

John Varian COO

ARYx Directors

Nicholas Simon Director

ARYx Fundamentals

Working Capital vs Cash per Share
One Year High vs Current Valuation
Working Capital vs Cash and Equivalents
Market Capitalization vs Current Valuation

ARYx vs Competition

ARYx vs. Federal National Mortgage Association
ARYx vs. Federal National Mortgage Association
ARYx vs. SK Innovation
ARYx vs. KDDI Corp
ARYx vs. Japan Tobacco Inc
ARYx vs. Inpex Corporation
ARYx vs. AP M
ARYx vs. AP M
ARYx vs. Citigroup Inc
ARYx vs. Akbank TAS

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium